CD4+ T细胞在PD-1阻断治疗MHC-II阳性经典型霍奇金淋巴瘤中的关键作用
本研究探讨MHC-II/CD4+ T细胞轴在PD-1阻断治疗经典型霍奇金淋巴瘤(cHL)抗肿瘤效应中的作用。cHL中MHC-I表达常缺失而MHC-II表达保留,CD4+ T细胞高度浸润MHC-II阳性cHL肿瘤微环境,且CD4+ T细胞浸润(而非CD8+ T细胞)为良好预后因素。小鼠淋巴瘤与实体瘤模型显示抗PD-1抗体以细胞毒性CD4+ T细胞依赖方式对MHC-I-MHC-II+肿瘤发挥抗肿瘤作用,LAG-3阻断与PD-1阻断联合抗肿瘤免疫显著增强。
要点
- cHL中MHC-II表达保留,CD4+ T细胞高度浸润肿瘤微环境
- CD4+ T细胞浸润是cHL良好预后因素,PD-1阻断疗效与CD4+ T细胞浸润相关
- LAG-3阻断联合PD-1阻断抗肿瘤免疫显著强于单药
核心结论
- PD-1阻断对cHL等MHC-II表达肿瘤的抗肿瘤效应由细胞毒性CD4+ T细胞介导
- LAG-3可作为PD-1阻断联合治疗的候选靶点
研究设计与样本
- cHL临床样本分析MHC-I/MHC-II表达与CD4+/CD8+ T细胞浸润及预后关系
- 小鼠淋巴瘤与实体瘤模型验证抗PD-1抗体的抗肿瘤效应及CD4+ T细胞依赖性
主要发现
- cHL中MHC-I表达常缺失而MHC-II表达保留
- MHC-II阳性cHL中CD4+ T细胞高度浸润,与MHC-I表达状态无关
- CD4+ T细胞(而非CD8+ T细胞)浸润为cHL良好预后因素
- 抗PD-1抗体对MHC-I-MHC-II+肿瘤有抗肿瘤效应,对MHC-I-MHC-II-肿瘤无效应,呈细胞毒性CD4+ T细胞依赖
- MHC-II表达肿瘤中肿瘤浸润CD4+ T细胞高表达LAG-3,LAG-3阻断联合PD-1阻断抗肿瘤免疫远强于单药
临床怎么用
- cHL等MHC-II表达肿瘤可考虑PD-1阻断治疗,疗效与CD4+ T细胞浸润相关
- LAG-3阻断联合PD-1阻断可能增强抗肿瘤免疫,值得进一步临床研究
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Classic Hodgkin lymphoma (cHL) responds markedly to PD-1 blockade therapy, and the clinical responses are reportedly dependent on expression of major histocompatibility complex class II (MHC-II). This dependence is different from other solid tumors, in which the MHC class I (MHC-I)/CD8+ T-cell axis plays a critical role. In this study, we investigated the role of the MHC-II/CD4+ T-cell axis in the antitumor effect of PD-1 blockade on cHL. In cHL, MHC-I expression was frequently lost, but MHC-II expression was maintained. CD4+ T cells highly infiltrated the tumor microenvironment of MHC-II-expressing cHL, regardless of MHC-I expression status. Consequently, CD4+ T-cell, but not CD8+ T-cell, infiltration was a good prognostic factor in cHL, and PD-1 blockade showed antitumor efficacy against MHC-II-expressing cHL associated with CD4+ T-cell infiltration. Murine lymphoma and solid tumor models revealed the critical role of antitumor effects mediated by CD4+ T cells: an anti-PD-1 monoclonal antibody exerted antitumor effects on MHC-I-MHC-II+ tumors but not on MHC-I-MHC-II- tumors, in a cytotoxic CD4+ T-cell-dependent manner. Furthermore, LAG-3, which reportedly binds to MHC-II, was highly expressed by tumor-infiltrating CD4+ T cells in MHC-II-expressing tumors. Therefore, the combination of LAG-3 blockade with PD-1 blockade showed a far stronger antitumor immunity compared with either treatment alone. We propose that PD-1 blockade therapies have antitumor effects on MHC-II-expressing tumors such as cHL that are mediated by cytotoxic CD4+ T cells and that LAG-3 could be a candidate for combination therapy with PD-1 blockade.
引用
- Nagasaki J, Togashi Y, Sugawara T, et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv. 2020. PMID: 32870971. doi:10.1182/bloodadvances.2020002098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。